Fate Therapeutics, Inc. (FATE) CEO Scott Wolchko on Q4 2019 Results - Earnings Call Transcript [Seeking Alpha]
Fate Therapeutics, Inc. (FATE)
Last fate therapeutics, inc. earnings: 3/2 04:01 pm
Check Earnings Report
US:NASDAQ Investor Relations:
ir.fatetherapeutics.com/investor-relations
Company Research
Source: Seeking Alpha
Fate Therapeutics, Inc. (NASDAQ: FATE Company Participants Scott Wolchko - President and Chief Executive Officer Daniel Shoemaker - Chief Scientific Officer Wayne Chu - Senior Vice President of Clinical Development Conference Call Participants Mara Goldstein - Mizuho Securities USA LLC Alethia Young - Cantor Fitzgerald & Co. James Birchenough - Wells Fargo Securities, LLC Edward Tenthoff - Piper Sandler & Co. Benjamin Burnett - Stifel, Nicolaus & Company, Inc. Kelsey Goodwin - Guggenheim Securities, LLC Biren Amin - Jefferies LLC Matthew Biegler - Oppenheimer & Co. Inc. Amanda Murphy - BTIG, LLC Operator Welcome to the Fate Therapeutics' Fourth Quarter 2019 Financial Results Conference Call. At this time, all participants are in a listen-only mode. This call is being webcast live on the Investors and Media section of Fate's website at fatetherapeutics.com. As a reminder, today's call is being recorded. I would now like to introduce Scott Wolchko, President and CEO of Fate Therapeutics
Show less
Read more
Impact Snapshot
Event Time:
FATE
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
FATE alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
FATE alerts
High impacting Fate Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
FATE
News
- Fate Therapeutics: Looking For A Potential Turnaround In 2024 [Seeking Alpha]Seeking Alpha
- Fate Therapeutics, Inc. (NASDAQ: FATE) had its "neutral" rating re-affirmed by analysts at Wedbush. They now have a $7.00 price target on the stock.MarketBeat
- Fate Therapeutics Announces Presentation of FT819 Proof-of-Concept Data for B cell-mediated Autoimmune Diseases at ASGCT Annual Meeting [Yahoo! Finance]Yahoo! Finance
- Fate Therapeutics Announces Presentation of FT819 Proof-of-Concept Data for B cell-mediated Autoimmune Diseases at ASGCT Annual MeetingGlobeNewswire
- Fate Therapeutics, Inc. (NASDAQ: FATE) had its "hold" rating re-affirmed by analysts at Needham & Company LLC.MarketBeat
FATE
Earnings
- 2/26/24 - Beat
FATE
Sec Filings
- 4/30/24 - Form EFFECT
- 4/26/24 - Form ARS
- 4/26/24 - Form DEFA14A
- FATE's page on the SEC website